Trimethylaminuria associated with seizures and behavioural disturbance: a case report
The first head-to-head clinical trial (SURMOUNT-5, published in NEJM 2025) showed tirzepatide produced 20.2% average weight loss at 72 weeks versus 13.7% for semaglutide approximately 47% greater relative weight loss
12% for daily peptide-support skincare
The conversion between GSH and GSSG is enzymatic, and the two enzymes that run the cycle are among the most-studied catalysts in cellular biology
Statistical significance in c , d, f, g and h was determined by one-way ANOVA followed by Bonferroni post-hoc analysis
However, the interpretation of these findings requires careful consideration of methodological challenges including confounding variables, exposure misclassification, and the inherent complexity of dose-response relationships